FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 320:8-13 January 5, 1989 Number 1 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We conducted a controlled trial to investigate the long-term effects of treatment with methylprednisolone and chlorambucil in patients with idiopathic membranous nephropathy. We have previously reported that after a mean of 31 months, treated patients did better. We now report the results of a longer follow-up. Eighty-one patients with proteinuria (greater than or equal to 3.5 g per day) and biopsy-proved membranous nephropathy were randomly assigned to receive either supportive therapy alone or a six-month course of corticosteroids alternated with chlorambucil (0.2 mg per kilogram of body weight per day) every other month. Methylprednisolone was first given intravenously in three pulses (1 g per day) and was then given orally (0.4 mg per kilogram per day) for 27 days. The patients were followed for 2 to 11 years (median, 5). Two patients in the control group and one in the treatment group died. At the last follow-up visit, 9 of 39 patients assigned to the control group (23 percent) and 28 of 42 patients assigned to the treatment group (67 percent) did not have the nephrotic syndrome. At five years there were more remissions of the nephrotic syndrome in treated patients than in controls (22 of 30 vs. 10 of 25; P = 0.026). Compared with base-line values, the mean reciprocal of the plasma creatinine level declined significantly in the control group (33 percent; P = 0.0002) but not in the treatment group (6 percent; P not significant). Plasma creatinine increased by 50 percent or more in 19 controls (49 percent) and in 4 treated patients (10 percent). We conclude that a six-month course of methylprednisolone and chlorambucil can bring about sustained remission of the nephrotic syndrome and help to preserve renal function in patients with idiopathic membranous nephropathy.

Source Information

Division of Nephrology, Ospedale Maggiore Milano, Italy.

This article has been cited by other articles:

• Eriguchi, M., Oka, H., Mizobuchi, T., Kamimura, T., Sugawara, K., Harada, A. (2009). Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant 24: 3082-3088 [Abstract] [Full Text]  
• Bomback, A. S., Derebail, V. K., McGregor, J. G., Kshirsagar, A. V., Falk, R. J., Nachman, P. H. (2009). Rituximab Therapy for Membranous Nephropathy: A Systematic Review. CJASN 4: 734-744 [Abstract] [Full Text]  
• Senthil Nayagam, L., Ganguli, A., Rathi, M., Kohli, H. S., Gupta, K. L., Joshi, K., Sakhuja, V., Jha, V. (2008). Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 23: 1926-1930 [Abstract] [Full Text]  
• Fervenza, F. C., Sethi, S., Specks, U. (2008). Idiopathic Membranous Nephropathy: Diagnosis and Treatment. CJASN 3: 905-919 [Abstract] [Full Text]  
• Cravedi, P., Ruggenenti, P., Sghirlanzoni, M. C., Remuzzi, G. (2007). Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy. CJASN 2: 932-937 [Abstract] [Full Text]  
• Glassock, R. J. (2007). Prophylactic Anticoagulation in Nephrotic Syndrome: A Clinical Conundrum. J. Am. Soc. Nephrol. 18: 2221-2225 [Abstract] [Full Text]  
• Jha, V., Ganguli, A., Saha, T. K., Kohli, H. S., Sud, K., Gupta, K. L., Joshi, K., Sakhuja, V. (2007). A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy. J. Am. Soc. Nephrol. 18: 1899-1904 [Abstract] [Full Text]  
• Tse, K C, Lam, M F, Tang, S C., Tang, C S., Chan, T M (2007). A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 16: 46-51 [Abstract]  
• Pape, L., Mengel, M., Offner, G., Ehrich, J. H.H. (2004). Cyclosporin A-induced remission of primary membranous glomerulonephritis in a child. Nephrol Dial Transplant 19: 3207-3207 [Full Text]  
• du Buf-Vereijken, P.W.G., Feith, G.W., Hollander, D., Gerlag, P.G.G., Wirtz, J.J.J.M., Noordzij, T.C., Wetzels, J.F.M. (2004). Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort. QJM 97: 353-360 [Abstract] [Full Text]  
• Nachman, P. H., Martin, J. (2002). Developments in the Immunotherapy of Glomerular Disease. Journal of Pharmacy Practice 15: 472-489 [Abstract]  
• SCHWARZ, A. (2001). New Aspects of the Treatment of Nephrotic Syndrome. J. Am. Soc. Nephrol. 12: S44-S47 [Abstract] [Full Text]  
• Kacker, A., Kuhel, W. I., Hoda, R. S. (2000). Quiz Case 2. Arch Otolaryngol Head Neck Surg 126: 677-682 [Full Text]  
• NEUGARTEN, J., ACHARYA, A., SILBIGER, S. R. (2000). Effect of Gender on the Progression of Nondiabetic Renal Disease: AMeta-Analysis. J. Am. Soc. Nephrol. 11: 319-329 [Abstract] [Full Text]  
• Tang, S., Chan, T.M., Cheng, I.K.P., Lai, K.N. (1999). Clinical features and treatment outcome of idiopathic membranous nephropathy in Chinese patients. QJM 92: 401-406 [Abstract] [Full Text]  
• Saiz, A., Arpa, J., Sagasta, A., Casamitjana, R., Zarranz, J. J., Tolosa, E., Graus, F. (1997). Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology 49: 1026-1030 [Abstract] [Full Text]  
• Mason, P D, Pusey, C D (1994). Fortnightly Review: Glomerulonephritis: diagnosis and treatment. BMJ 309: 1557-1563 [Abstract] [Full Text]  
• Schieppati, A., Mosconi, L., Perna, A., Mecca, G., Bertani, T., Garattini, S., Remuzzi, G. (1993). Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. NEJM 329: 85-89 [Abstract] [Full Text]  
• Lewis, E. J. (1993). Idiopathic Membranous Nephropathy -- To Treat or Not to Treat?. NEJM 329: 127-129 [Full Text]  
• Austin, H. A. III, Antonovych, T. T., MacKay, K., Boumpas, D. T., Balow, J. E. (1992). Membranous Nephropathy. ANN INTERN MED 116: 672-682 [Abstract]  
• Falk, R. J., Hogan, S. L., Muller, K. E., Jennette, J. C., Glomerular Disease Collaborative Network, (1992). Treatment of Progressive Membranous Glomerulopathy: A Randomized Trial Comparing Cyclophosphamide and Corticosteroids with Corticosteroids Alone. ANN INTERN MED 116: 438-445 [Abstract]  
• Bruns, F. J., Adler, S., Fraley, D. S., Segel, D. P. (1991). Sustained Remission of Membranous Glomerulonephritis after Cyclophosphamide and Prednisone. ANN INTERN MED 114: 725-730 [Abstract]